Recent SMMT News
- HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024 • Business Wire • 08/12/2024 11:00:00 AM
- Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024 • PR Newswire (US) • 08/11/2024 11:30:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/09/2024 08:15:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 08/06/2024 01:03:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 11:37:21 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 11:14:08 AM
- Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024 • Business Wire • 08/06/2024 11:00:00 AM
- Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024 • Business Wire • 07/29/2024 08:15:00 PM
- Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab • Business Wire • 07/25/2024 12:00:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 07/03/2024 08:15:00 PM
- Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors • Business Wire • 06/27/2024 08:15:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 06/18/2024 09:14:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 09:25:01 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/13/2024 06:03:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 10:18:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 10:05:37 AM
- Summit Raises $200 Million; Also Expands License Territories for Ivonescimab • Business Wire • 06/03/2024 09:30:00 AM
- Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA • Business Wire • 06/01/2024 12:00:00 PM
- Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy • Business Wire • 05/31/2024 11:00:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/30/2024 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:48:30 PM
- Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China • Business Wire • 05/30/2024 06:29:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 12:35:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:03:57 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/13/2024 11:48:42 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM